New combo shows promise for rare kidney cancers
NCT ID NCT05808608
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is to see if the combo can shrink tumors and how safe it is.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHROMOPHOBE RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a drug combo outperform standard therapy for a rare kidney cancer?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a targeted pill boost Chemo's power against a rare blood cancer?
- Can a new nucleotide analogue boost cancer treatment?